Bioiberica

Palafolls, Spain

Bioiberica

Palafolls, Spain
SEARCH FILTERS
Time filter
Source Type

MADRID--(BUSINESS WIRE)--Las últimas evidencias publicadas sobre el tratamiento de la osteoartritis se ha presentado hoy en el simposio organizado por Bioiberica e IBSA en el Congreso Anual Europeo de Reumatología, que se celebra en Madrid (España). Un nuevo ensayo clínico, elaborado por IBSA y denominado CONCEPT (ChONdroitin vs CElecoxib vs Placebo Trial- ensayo de comparación de condroitina, celecoxib y placebo), desvela que el sulfato de condroitina de clase farmacéutica es tan efectivo como


Eine neue klinische Studie mit der Bezeichnung CONCEPT (ChONdroitin vs CElecoxib vs Placebo Trial), die IBSA durchgeführt hat, zeigt, dass Chondroitinsulfat pharmakologischer Stärke in Bezug auf die Schmerzreduktion und Verbesserung der funktionellen Beeinträchtigung bei Patienten mit Kniegelenksarthrose so wirksam wie ein entzündungshemmendes Arzneimittel (Celecoxib) und einem Placebo überlegen ist. Es handelt sich um eine multizentrische, randomisierte, doppelblinde Double-Dummy-Studie der Phase III, an der 604 Patienten mit Kniegelenksarthrose aus 16 Zentren in Belgien, der Tschechischen Republik, Italien, Polen und der Schweiz teilgenommen haben, um die symptomatischen Wirkungen von Chondroitinsulfat (800 mg/Tag) und Celecoxib (200 mg/Tag) gegenüber einem Placebo zu untersuchen. Eine multizentrische, randomisierte, doppelblinde, kontrollierte und vergleichende Studie, die Bioiberica unter der Bezeichnung MOSAIC (24 MOnth study on Structural changes in knee osteoarthritis Assessed by mrI with Chondroitin sulfate) in fünf medizinischen Zentren in Quebec (Kanada) durchgeführt hat, zeigt, dass Chondroitinsulfat die Progredienz der Krankheit verlangsamt und so wirksam wie Celecoxib bei der Verbesserung der Arthrosesymptome ist. Für die Studie wurden 194 Patienten rekrutiert, die an Kniegelenksarthrose mit Entzündung (Synovitis) und mittelstarken Schmerzen litten, um die Wirkung von Chondroitinsulfat (1.200 mg/Tag) und Celecoxib (200 mg/Tag) in Bezug auf den Verlust an Knorpelvolumen bei der Kniearthrose nach 24 Monaten zu prüfen. Die Teilnehmer unterzogen sich drei quantitativen Magnetresonanztomographien und die Ergebnisse zeigten, dass die Kniegelenksarthrose bei Patienten, die Chondroitinsulfat einnahmen, langsamer fortschritt. Genauer gesagt zeigte sich in dieser Gruppe ein statistisch signifikant niedrigerer Verlust an Knorpelvolumen bereits nach dem ersten Behandlungsjahr im Vergleich zu Patienten, die den Entzündungshemmer einnahmen.


MADRID--(BUSINESS WIRE)--The latest published evidence on osteoarthritis treatment has been presented today at the symposium organized by Bioiberica and IBSA at the Annual European Congress of Rheumatology, being held in Madrid, Spain. A new clinical trial, carried out by IBSA and called CONCEPT (ChONdroitin vs CElecoxib vs Placebo Trial), shows that pharmaceutical grade chondroitin sulfate is as effective as an anti-inflammatory drug (celecoxib) and superior to placebo for pain reduction and improvement of functional disability in patients with knee osteoarthritis. This is a phase III, multicenter, randomized, double-blind, double-dummy study, that enrolled 604 patients from 16 centers in Belgium, Czech Republic, Italy, Poland, and Switzerland with knee osteoarthritis to investigate the symptomatic effects of chondroitin sulfate (800 mg/day) and celecoxib (200 mg/day) as compared to placebo. “A great controversy still exists as to which should be the treatment of choice for osteoarthritis. Analgesics and anti-inflammatory drugs have traditionally been used, but they are increasingly associated to toxicity warnings. This trial has provided statistically significant evidence that treatment with pharmaceutical grade chondroitin sulfate is an effective and safe alternative for long-term treatment of patients with knee osteoarthritis” according to Dr. Tomasz Blicharski, Department of Rehabilitation and Traumatology of Lublin University (Poland) and investigator of the study. A multicenter, randomized, double blind, controlled and comparative study, conducted by Bioiberica and named MOSAIC (24 MOnth study on Structural changes in knee osteoarthritis Assessed by mrI with Chondroitin sulfate), carried out in five medical centers in Quebec (Canada), shows that chondroitin sulfate delays the disease’s progression and is as effective as celecoxib improving osteoarthritis symptoms. The study recruited 194 patients suffering from knee osteoarthritis with inflammation (synovitis) and moderate pain, to assess the effects of chondroitin sulfate (1.200 mg/ day) and celecoxib (200 mg/ day) over the loss of cartilage volume in knee osteoarthritis after 24 months. The participants underwent three Quantitative Magnetic Resonance scans and the results revealed that the progression of knee osteoarthritis is slower in patients receiving chondroitin sulfate. More precisely, this group experienced a statistically significant lower loss of cartilage volume as soon as after the first year of treatment, in comparison with those patients who received the anti inflammatory drug. The study also evaluated the effects of both products on the disease’s symptoms concluding that both treatments were equally efficient across the entire study, reaching a clinically relevant symptom improvement of around 50%. “All this latest evidence presented today proves that chondroitin sulfate complies with the requirements that an osteoarthritis treatment must fulfill: it improves pain and functional capacity, and it delays the disease’s progression while having a good safety profile, something essential in a chronic disease such as osteoarthritis”, concluded Professor Jean Pierre Pelletier, main investigator of the MOSAIC study.


MADRID--(BUSINESS WIRE)--Het actueelste gepubliceerde bewijs over de behandeling van osteoarthritis is vandaag gepresenteerd op het symposium dat Bioiberica en IBSA hebben georganiseerd op het jaarlijkse European Congress of Rheumatology, in Madrid. Het nieuwe klinisch-wetenschappelijke onderzoek CONCEPT (ChONdroitin vs CElecoxib vs Placebo Trial), uitgevoerd door IBSA, laat zien dat chondroïtinesulfaat van farmaceutische klasse even effectief is als een ontstekingsremmend medicijn (celecoxib) en beter werkt dan een placebo voor wat betreft pijnbestrijding en functionele verbetering bij patiënten met osteoarthritis aan de knie. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.


MADRID--(BUSINESS WIRE)--I dati più recenti pubblicati sul trattamento dell’osteoartrite sono stati oggi presentati al simposio organizzato da Bioiberica e dall’IBSA all’Annual European Congress of Rheumatology, in corso di svolgimento a Madrid, in Spagna. Un nuovo studio clinico dell’IBSA, dal nome CONCEPT (ChONdroitin vs CElecoxib vs Placebo Trial), dimostra che il condroitin solfato di grado farmaceutico ha un’efficacia equivalente agli antinfiammatori (celecoxib) e superiore rispetto al placebo per la riduzione del dolore e il miglioramento della capacità funzionale nei pazienti affetti da osteoartrite del ginocchio. Per lo studio di fase III, multicentrico, randomizzato, in doppio cieco e double-dummy, sono stati arruolati 604 pazienti di 16 centri in Belgio, Repubblica Ceca, Italia, Polonia e Svizzera affetti da osteoartrite al ginocchio per studiare gli effetti sintomatici del condroitin solfato (800 mg/giorno) e di celecoxib (200 mg/giorno) rispetto al placebo.


Un nouvel essai clinique, appelé CONCEPT (ChONdroitin vs CElecoxib vs Placebo Trial [essai comparant la chondroïtine, le célécoxib et un placebo]) et réalisé par IBSA, montre que le sulfate de chondroïtine de qualité pharmaceutique est aussi efficace qu’un anti-inflammatoire (célécoxib) et supérieur à un placebo pour réduire la douleur et améliorer le handicap fonctionnel des patients atteints d’arthrose du genou. Il s’agit d’une étude de phase III multicentrique, randomisée, en double aveugle et double placebo portant sur 604 patients dans 16 centres en Belgique, dans la République tchèque, en Italie, en Pologne et en Suisse et visant à évaluer les effets symptomatiques du sulfate de chondroïtine (800 mg/jour) et du célécoxib (200 mg/jour) par rapport à un placebo. « Le traitement de choix de l’arthrose fait toujours l’objet d’une grande controverse. Les analgésiques et les anti-inflammatoires sont couramment utilisés mais ils sont de plus en plus associés à des risques de toxicité. Cet essai a prouvé de façon statistiquement significative que le sulfate de chondroïtine de qualité pharmaceutique est une option sûre et efficace pour le traitement à long terme des patients atteints d’arthrose du genou », selon le Dr Tomasz Blicharski, service de réhabilitation et de traumatologie de l’Université de Lublin (Pologne) et investigateur de l’étude. Une étude comparative multicentrique, randomisée, en double aveugle et contrôlée, appelée MOSAIC (24 MOnth study on Structural changes in knee osteoarthritis Assessed by mrI with Chondroitin sulfate [étude de 24 mois sur les modifications structurelles de l’arthrose du genou évaluées par LMR avec le sulfate de chondroïtine]), réalisée par Bioiberica dans cinq centres médicaux au Québec (Canada), montre que le sulfate de chondroïtine ralentit la progression de la maladie et est aussi efficace que le célécoxib pour améliorer les symptômes de l’arthrose. L’étude a recruté 194 patients atteints d’arthrose du genou accompagnée d’inflammation (synovite) et de douleurs modérées et a évalué les effets du sulfate de chondroïtine (1 200 mg/jour) et du célécoxib (200 mg/jour) sur la perte du volume de cartilage dans l’arthrose du genou après 24 mois. Les participants ont subi trois examens quantitatifs par imagerie à résonance magnétique et les résultats ont montré que la progression de l’arthrose du genou est plus lente chez les patients recevant du sulfate de chondroïtine. Plus précisément, ce groupe a présenté une diminution statistiquement significative de la perte de volume du cartilage dès la première année de traitement, par rapport aux patients ayant reçu un anti-inflammatoire.


Lambert C.,University of Liège | Dubuc J.-E.,Cliniques Universitaires Saint Luc | Montell E.,Bioiberica | Verges J.,Bioiberica | And 3 more authors.
Arthritis and Rheumatology | Year: 2014

Objective To compare the gene expression patterns of synovial cells from inflamed or normal/reactive areas of synovial membrane obtained from the same patient with osteoarthritis (OA). Methods At the time of total knee replacement, synovial tissues were obtained from 12 patients with knee OA. The inflammation status of the synovial membrane was characterized according to macroscopic criteria and classified as normal/reactive or inflamed. Biopsy samples were cultured separately for 7 days. Microarray gene expression profiling was performed on normal/reactive and inflamed areas. Western blot and immunohistochemistry were used to confirm the identified genes that were differentially expressed. Results We identified 896 genes that were differentially expressed between normal/reactive and inflamed areas. The key pathways were related to inflammation, cartilage metabolism, Wnt signaling, and angiogenesis. In the inflammation network, the genes TREM1 and S100A9 were strongly up-regulated. The genes MMP3, MMP9, CTSH (cathepsin H), and CTSS (cathepsin S) were significantly up-regulated in the cartilage catabolism pathway, while the most up-regulated anabolism enzyme gene was HAS1. In the Wnt signaling pathway, the genes for Wnt-5a and low-density lipoprotein receptor-related protein 5 were up-regulated, while the gene FZD2 and the gene for Dkk-3 were down-regulated. Finally, STC1, which codes for a protein involved in angiogenesis, was identified as the most up-regulated gene in inflamed compared with normal/reactive areas. Conclusion This study is the first to identify different expression patterns between 2 areas of the synovial membrane from the same patient. These differences concern several key pathways involved in OA pathogenesis. This analysis also provides information regarding new genes and proteins as potential targets of treatment. © 2014 The Authors. Arthritis & Rheumatology is published by Wiley Periodicals, Inc. on behalf of the American College of Rheumatology.


Trademark
Bioiberica | Date: 2013-08-16

Chemical products for stabilizing foodstuffs; Chemical preparations for preserving foodstuffs; chemical products for use in the pharmaceutical, nutraceutical, infant nutrition, medical nutrition and functional food industries, namely, chemical substances for use in the manufacture of pharmaceuticals, nutraceutical, infant nutrition, medical nutrition and functional food products; all of the foregoing containing Omega-3. Pharmaceutical products for the treatment of joint pain, osteoarthritis, dry skin, psychiatric disorders, alzheimers, cognitive health; for use in dermatology or for as an anticoagulant; chemico-pharmaceutical products for the treatment of joint pain, osteoarthritis, dry skin, psychiatric disorders, alzheimers, cognitive health; for use in dermatology or for as an anticoagulant; and for treatment of cardiovascular and vascular diseases; chemical products for pharmaceutical purposes, namely, medicated polymer-based preparations for the treatment of cardiovascular and vascular diseases; chemical products for pharmaceutical and neutraceutical use, namely, nutritional supplements; dietary and nutritional supplements; pharmaceutical products; dietetic substances for medical use, namely, diet capsules and diet pills, food supplements for medical use, mineral food supplements and food supplements based on amino acids, glycosaminoglycans, minerals, vitamins and/or trace elements; dietetic foods for medical use, namely, dietetic fiber; all the aforesaid goods in galenic form as powders, capsules, pills or liquids, all exclusively for human consumption and comprising omega fatty acids. Meat, fish, poultry and game; meat extracts; preserved, frozen, dried and cooked fruits and vegetables; fruit jellies, jams, compotes; eggs; milk and dairy products excluding ice cream, ice milk and frozen yogurt; edible oils and fats; all of the above made in whole or part of Omega-3.


Trademark
Bioiberica | Date: 2015-09-07

Native, not denatured collagen used as a raw ingredient in the manufacture of food and supplements for use in the food and pharmaceutical industry for health relating to joints.


Trademark
Bioiberica | Date: 2014-05-21

Chemical products for use in industry, science, photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins, unprocessed plastics; soil fertilizers; fire extinguishing compositions; tempering and soldering preparations; chemicals for preserving foodstuffs; tanning substances; adhesives for use in industry. Meat, fish, poultry and game; meat extracts; preserved, frozen, dried and cooked fruit and vegetables; jellies, jams, compotes; eggs, milk and dairy products; edible oils and fats. Beers; mineral and aerated waters and other non-alcoholic beverages; fruit beverages and juices; syrups and other preparations for making beverages.

Loading Bioiberica collaborators
Loading Bioiberica collaborators